Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...

Protagonist Therapeutics (PTGX) is gearing up to report top-line results from its phase 3 VERIFY study using its subcutaneous injectable Hepcidin Mimetic rusfertide [PTG-300] for the treatment of ...

London-based sales, finance and production company Protagonist Pictures has launched a boutique label on the eve of Cannes. Announced by Protagonist CEO Dave Bishop, Protagonist Picks will be led by ...